文献速递炎症性肠病消化内镜

人工智能辅助结肠镜实时预测溃疡性结肠炎复发的前瞻性研究

Evaluation in real-time use of artificial intelligence during colonoscopy to predict relapse of ulcerative colitis: a prospective study.
PubMed 文献 · Gastrointest Endosc · 2021-10-22

该开放标签前瞻性队列研究在转诊中心纳入145例临床缓解期溃疡性结肠炎患者,行AI辅助结肠镜并据实时输出分为愈合组与活动组。135例完成12个月随访,AI活动组临床复发率28.4%显著高于愈合组4.9%(P<.001),提示实时AI有助于分层复发风险并辅助治疗决策。

要点

  • AI辅助结肠镜可实时将临床缓解期UC患者分为愈合组与活动组。
  • AI活动组12个月临床复发率28.4%,显著高于愈合组的4.9%。
  • 实时AI输出有助于临床医生即时决策是否调整治疗干预。

核心结论

  • 实时使用AI可预测临床缓解期溃疡性结肠炎患者的临床复发风险,有助于医生实时做出治疗干预决策。

研究设计与样本

  • 开放标签、前瞻性队列研究,在转诊中心连续纳入145例临床缓解期接受AI辅助结肠镜(具接触显微功能)的溃疡性结肠炎患者。
  • 根据结肠镜中AI输出将患者分为愈合组与活动组,主要终点为结肠镜后12个月内临床复发(部分Mayo评分>2)。
  • 共135例完成12个月随访;AI辅助结肠镜分类61例为愈合组、74例为活动组。

主要发现

  • AI活动组复发率为28.4%(21/74;95%CI 18.5%-40.1%),显著高于AI愈合组的4.9%(3/61;95%CI 1.0%-13.7%;P<.001)。

关键数值与推荐

  • 临床复发定义为部分Mayo评分>2。
  • AI活动组12个月复发率28.4%(21/74;95%CI 18.5%-40.1%)。
  • AI愈合组12个月复发率4.9%(3/61;95%CI 1.0%-13.7%)。
  • 组间复发率比较P<.001。

临床怎么用

  • 对临床缓解期溃疡性结肠炎患者,可在结肠镜中实时使用AI输出分层复发风险。
  • AI判定为活动组的患者复发风险较高,可辅助医生实时决定治疗干预。

局限性

  • 开放标签设计。
  • 单中心转诊中心研究。
  • 145例中135例完成12个月随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The use of artificial intelligence (AI) during colonoscopy is attracting attention as an endoscopist-independent tool to predict histologic disease activity of ulcerative colitis (UC). However, no study has evaluated the real-time use of AI to directly predict clinical relapse of UC. Hence, it is unclear whether the real-time use of AI during colonoscopy helps clinicians make real-time decisions regarding treatment interventions for patients with UC. This study aimed to establish the role of real-time AI in stratifying the relapse risk of patients with UC in clinical remission. METHODS: This open-label, prospective, cohort study was conducted in a referral center. The cohort comprised 145 consecutive patients with UC in clinical remission who underwent AI-assisted colonoscopy with a contact-microscopy function. We classified patients into either the Healing group or Active group based on the AI outputs during colonoscopy. The primary outcome measure was clinical relapse of UC (defined as a partial Mayo score >2) during 12 months of follow-up after colonoscopy. RESULTS: Overall, 135 patients completed the 12-month follow-up after AI-assisted colonoscopy. AI-assisted colonoscopy classified 61 patients as the Healing group and 74 as the Active group. The relapse rate was significantly higher in the AI-Active group (28.4% [21/74]; 95% confidence interval, 18.5%-40.1%) than in the AI-Healing group (4.9% [3/61]; 95% confidence interval, 1.0%-13.7%; P < .001). CONCLUSIONS: Real-time use of AI predicts the risk of clinical relapse in patients with UC in clinical remission, which helps clinicians make real-time decisions regarding treatment interventions. (Clinical trial registration number: UMIN000036650.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Maeda Y, Kudo SE, Ogata N, et al. Evaluation in real-time use of artificial intelligence during colonoscopy to predict relapse of ulcerative colitis: a prospective study. Gastrointest Endosc. 2021. PMID: 34695422. doi:10.1016/j.gie.2021.10.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。